Aridis Pharmaceuticals, Inc. (common stock) is reported to have 5,096,251 shares beneficially owned by Armistice Capital Master Fund Ltd., with Armistice Capital, LLC and Steven Boyd deemed reporting persons. This position represents 11.43% of the outstanding common stock.
Armistice Capital, a Delaware investment adviser, exercises shared voting and dispositive power over all 5,096,251 shares under an Investment Management Agreement with the Master Fund; neither Armistice Capital nor Steven Boyd has sole voting or dispositive power. The Master Fund, a Cayman Islands exempted company, has the right to receive dividends and sale proceeds from these securities.
Aridis Pharmaceuticals, Inc. ownership update: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 5,096,251 shares of Common Stock, representing 11.43% of the class as reported on 03/31/2026. Armistice Capital states it exercises shared voting and dispositive power over these shares on behalf of Armistice Capital Master Fund Ltd.
Aridis Pharmaceuticals reports a Schedule 13G/A showing Armistice Capital, LLC and Steven Boyd beneficially own 5,096,251 shares, representing 11.43% of the common stock (CUSIP 040334104). The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and Mr. Boyd, as managing member, may be deemed to beneficially own the shares. The Master Fund is identified as the direct holder and is described as having the right to receive dividends or sale proceeds.